All In Biotech

Drug Trial Radar · NCT04889209

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

Last checked: Nov 20, 2026Latest source record: Apr 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

867

Actual

Start

May 28, 2021

Primary completion

Jun 16, 2023

Study completion Jun 16, 2023

Sponsor

Sponsor type
NIH
First posted
May 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A phase 1/2, open-label clinical trial in individuals, 18 years of age and older, who are in good health, have no known history of Coronavirus Disease 2019 (COVID-19) or Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, and meet all other eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of a delayed (\>/=12 weeks) vaccine boost on a range of Emergency Use Authorization (EUA)-dosed COVID-19 vaccines (mRNA-1273, and mRNA-1273.211 manufactured by ModernaTX, Inc.; BNT162b2 manufactured by Pfizer/BioNTech; or Ad26.COV2.S manufactured by Janssen Pharmaceuticals/Johnson \& Johnson). This is an adaptive design and may add arms (and increase sample size) as vaccines are awarded EUA and/or variant lineage spike vaccines are manufactured or become available. Enrollment will occur at up to twelve domestic clinical research sites. This study includes two cohorts. Cohort 1 will include approximately 880 individuals (50 subjects/group; Groups 1E-11E) greater than 18 years of age and older, stratified into two age strata (18-55 years and \>/=56 years) who previously received COVID-19 vaccine at Emergency Use Authorization dosing (EUA) (two vaccinations of mRNA-1273 at the 100 mcg dose, two vaccinations of BNT162b2 at the 30 mcg dose, or one vaccination of Ad26.COV2.S at the 5x10\^10 vp dose). Groups 15E-17E will enroll 60 subjects, split (approximately evenly) between age strata as able. Those subjects will be offered enrollment into this study \>/=12 weeks after they received the last dose of their EUA vaccine. Subjects will receive a single open-label intramuscular (IM) injection of the designated delayed booster vaccine and will be followed through 12 months after vaccination: 1) Group 1E - previously EUA-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10\^10 vp followed by a 100-mcg dose of mRNA-1273, Group 4E - previously EUA-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10\^10 vp followed by a 5x10\^10 vp dose of Ad26.COV2.S, Group 7E - previously EUA-dosed vaccination with Janssen - Ad26.COV.2.S 5x10\^10 vp followed by a 30-mcg dose of BNT162b2, Group 10E - previously EUA-dosed vaccination with Janssen - Ad26.COV2-S 5x10\^10 vp followed by a 100-mcg dose of mRNA-1273.211; Group 12E - previously EUA-dosed vaccination with Janssen - Ad26.COV2-S 5x10\^10 vp followed by a 50-mcg dose of mRNA-1273; Group 15E - previously EUA-dosed vaccination with Janssen (two doses for Group 15E) - Ad26.COV2.S at 5x1010 vp followed by a dose of NVX-CoV2373 (5 mcg Prototype SARS-CoV-2 rS vaccine with 50 mcg Matrix-M); 2) Group 2E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 100-mcg dose of mRNA-1273, Group 5E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 5x10\^10 vp dose of Ad26.COV2.S, Group 8E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 30-mcg dose of BNT162b2, Group 13E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 50-mcg dose of mRNA-1273; Group 16E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a dose of NVX-CoV2373 (5 mcg Prototype SARS-CoV2 rS vaccine with 50 mcg Matrix-M); 3) Group 3E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 100-mcg dose of mRNA-1273. Group 6E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 5x10\^10 vp dose of Ad26.COV2.S, Group 9E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 30-mcg dose of BNT162b2, Group 11E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 100-mcg dose of mRNA-1273.211. Group 14E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 50-mcg dose of mRNA-1273, Group 17E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a dose of NVX-CoV2373 (5 mcg Prototype SARS-CoV2 rS vaccine with 50 mcg Matrix-M). A telephone visit will occur one week after each primary EUA vaccination and one week after the booster dose. In person follow-up visits will occur on 14 days following completion of EUA vaccinations and on days 14, and 28 days after the booster dose, as well as 3, 6, and 12 months post the booster vaccination. Additional pools of subjects can be included if needed as additional COVID-19 vaccines are awarded EUA. The primary objectives of this study are 1) to evaluate the safety and reactogenicity of delayed heterologous or homologous vaccine doses after EUA dosed vaccines, and 2) to evaluate the breadth of the humoral immune responses of heterologous and homologous delayed boost regimens following EUA dosing.

Conditions

  • COVID-19

Interventions

  • Ad26.COV2.SBiological

    Formulated to contain 5x10\^10 virus particles of the Ad26 vector encoding the S glycoprotein of SARS-CoV-2. Each dose of the Ad26.COV2.S vaccine also includes sodium chloride, citric acid monohydrate, trisodium citrate dihydrate, polysorbate-80, 2-hydroxypropyl-ß-cyclodextrin, and ethanol. Ad26.COV2.S will be used undiluted to obtain the specified vp content in 0.5 mL doses. Each dose is 0.5 mL.

  • BNT162b2Biological

    A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2. Each vial contains up to six doses. BNT162b2 (250 mcg/0.5 mL) will be administered in diluted 0.3 mL doses (30 mcg/0.3 mL).

  • mRNA-1273Biological

    Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV). Doses are either 0.25 mL or 0.5 mL.

  • mRNA-1273.211Biological

    Lipid nanoparticle (LNP) dispersion containing 1:1 mix of mRNAs that encodes for the prefusion stabilized S protein of the B.1.351 variant SARS-CoV-2 strain and the prefusion stabilized S protein of the Wuhan-Hu-1 strain used in mRNA-1273. mRNA-1273.211 (0.2 mg/mL) will be administered in 0.5 mL doses (100 mcg/0.5 mL).

  • mRNA-1273.222Biological

    Formulated in the same way as the mRNA-1273 vaccine but contains 1:1 mix of mRNAs that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the prefusion stabilized S protein of the Wuhan-Hu-1 strain used in mRNA-1273.

  • SARS-CoV-2 rS/M1Biological

    SARS-CoV-2 rS Drug Substance containing the prototype Wuhan is formulated with saponin-based Matrix-M adjuvant in a buffer of 25 mM sodium phosphate (pH 7.2), 300 mM sodium chloride, and 0.01% (weight per volume \[w/v\]) polysorbate 80. NVX-Co-V2373 will be administered in 0.5 mL dose (5 mcg Prototype SARS-CoV-2 rS with 50 mcg Matrix-M adjuvant)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean of Area Under the Curve (AUC) of Antibody Against WA-1 S2-P for Cohort 1Time frame: Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 273, Day 366
  2. Geometric Mean of AUC of Antibody Against B.1.351 S2-P for Cohort 1Time frame: Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 273, Day 366
  3. Geometric Mean AUC of Antibody Against B.1.617.2 S2-P for Cohort 1Time frame: Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 273, Day 366
  4. Geometric Mean AUC of Antibody Against B.1.1.529 S2-P for Cohort 1Time frame: Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 273, Day 366
  5. Geometric Mean AUC of Antibody of Antibody Against WA-1 S2-P for Cohort 2Time frame: Day 1 Pre-Booster Dose 2, Day 15 Post-Booster Dose 2, Day 29 Post-Booster Dose 2, Day 91 Post-Booster Dose 2, Day 181 Post-Booster Dose 2
  6. Geometric Mean AUC of Antibody Against BA.1 S2-P for Cohort 2Time frame: Day 1 Pre-Booster Dose 2, Day 15 Post-Booster Dose 2, Day 29 Post-Booster Dose 2, Day 91 Post-Booster Dose 2, Day 181 Post-Booster Dose 2
  7. Geometric Mean AUC of Antibody Against BA.5 S2-P for Cohort 2Time frame: Day 1 Pre-Booster Dose 2, Day 15 Post-Booster Dose 2, Day 29 Post-Booster Dose 2, Day 91 Post-Booster Dose 2, Day 181 Post-Booster Dose 2
  8. Geometric Mean of Pseudovirus Neutralization Against D614G for Cohort 1Time frame: Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 273, Day 366
  9. Geometric Mean of Pseudovirus Neutralization Against B.1.351 for Cohort 1Time frame: Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 273, Day 366
  10. Geometric Mean of Pseudovirus Neutralization Against B.1.617.2 for Cohort 1Time frame: Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 273, Day 366
  11. Geometric Mean of Pseudovirus Neutralization Against B.1.1.529 for Cohort 1Time frame: Day 1 Pre-Booster Dose, Day 15, Day 29, Day 91, Day 181, Day 273, Day 366
  12. Geometric Mean of Pseudovirus Neutralization Against D614G for Cohort 2Time frame: Day 1 Pre-Vaccination 1, Day 43 Post-Vaccination 1, Day 15 Post-Booster Dose 1, Day 1 Pre-Booster Dose 2, Day 15 Post-Booster Dose 2, Day 29 Post-Booster Dose 2, Day 91 Post-Booster Dose 2, Day 181 Post-Booster Dose 2
  13. Geometric Mean of Pseudovirus Neutralization Against BA.1 for Cohort 2Time frame: Day 1 Pre-Vaccination 1, Day 43 Post-Vaccination 1, Day 15 Post-Booster Dose 1, Day 1 Pre-Booster Dose 2, Day 15 Post-Booster Dose 2, Day 29 Post-Booster Dose 2, Day 91 Post-Booster Dose 2, Day 181 Post-Booster Dose 2
  14. Geometric Mean of Pseudovirus Neutralization Against BA.4/5 for Cohort 2Time frame: Day 1 Pre-Vaccination 1, Day 43 Post-Vaccination 1, Day 15 Post-Booster Dose 1, Day 1 Pre-Booster Dose 2, Day 15 Post-Booster Dose 2, Day 29 Post-Booster Dose 2, Day 91 Post-Booster Dose 2, Day 181 Post-Booster Dose 2
  15. Geometric Mean of Pseudovirus Neutralization Against XBB.1 for Cohort 2Time frame: Day 1 Pre-Vaccination 1, Day 43 Post-Vaccination 1, Day 15 Post-Booster Dose 1, Day 1 Pre-Booster Dose 2, Day 15 Post-Booster Dose 2, Day 29 Post-Booster Dose 2, Day 91 Post-Booster Dose 2, Day 181 Post-Booster Dose 2
  16. Frequency of Any Unsolicited Adverse Events (AEs)Time frame: Day 1 through Day 29 for Cohort 1, 28 days post any vaccination in Cohort 2
  17. Frequency of Any Protocol Specified Adverse Events of Special Interest (AESIs)Time frame: For Cohort 1, Day 1 through Day 366; for Cohort 2, Day 1 through Day 590
  18. Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)Time frame: For Cohort 1, Day 1 through Day 366; for Cohort 2, Day 1 through Day 590
  19. Number of Participants With Any Medically-attended Adverse Events (MAAEs)Time frame: For Cohort 1, Day 1 through Day 366; for Cohort 2, Day 1 through Day 590
  20. Frequency of Any Serious Adverse Events (SAEs)Time frame: For Cohort 1, Day 1 through Day 366; for Cohort 2, Day 1 through Day 590
  21. Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)Time frame: Day 1 through Day 8 for Cohort 1, and through 7 days post any vaccination for Cohort 2
  22. Frequency of Local Solicited Reactogenicity Adverse Events (AEs)Time frame: Day 1 through Day 8 for Cohort 1, and through 7 days post any vaccination for Cohort 2
  23. Percent of Participants Who Seroconverted Against WA-1 S2-P for Cohort 1Time frame: Day 15, Day 29, Day 91, Day 181, Day 273, Day 366
  24. Percent of Participants Who Seroconverted Against B.1.351 S2-P for Cohort 1Time frame: Day 15, Day 29, Day 91, Day 181, Day 273, Day 366
  25. Percent of Participants Who Seroconverted Against B.1.617.2 S2-P for Cohort 1Time frame: Day 15, Day 29, Day 91, Day 181, Day 273, Day 366
  26. Percent of Participants Who Seroconverted Against B.1.1.529 S2-P for Cohort 1Time frame: Day 15, Day 29, Day 91, Day 181, Day 273, Day 366
  27. Percent of Participants Who Seroconverted Against WA-1 S2-P for Cohort 2Time frame: Day 15 Post-Booster Dose 2, Day 29 Post-Booster Dose 2, Day 91 Post-Booster Dose 2, Day 181 Post-Booster Dose 2
  28. Percent of Participants Who Seroconverted Against BA.1 S2-P for Cohort 2Time frame: Day 15 Post-Booster Dose 2, Day 29 Post-Booster Dose 2, Day 91 Post-Booster Dose 2, Day 181 Post-Booster Dose 2
  29. Percent of Participants Who Seroconverted Against BA.5 S2-P for Cohort 2Time frame: Day 15 Post-Booster Dose 2, Day 29 Post-Booster Dose 2, Day 91 Post-Booster Dose 2, Day 181 Post-Booster Dose 2
  30. Percent of Participants Who Seroconverted Against D614G for Cohort 1Time frame: Day 15, Day 29, Day 91, Day 181, Day 273, Day 366
  31. Percent of Participants Who Seroconverted Against B.1.351 for Cohort 1Time frame: Day 15, Day 29, Day 91, Day 181, Day 273, Day 366
  32. Percent of Participants Who Seroconverted Against B.1.617.2 for Cohort 1Time frame: Day 15, Day 29
  33. Percent of Participants Who Seroconverted Against B.1.1.529 for Cohort 1Time frame: Day 15, Day 29, Day 91, Day 181, Day 273, Day 366
  34. Percent of Participants Who Seroconverted Against D614G for Cohort 2Time frame: Day 43 Post-Dose 1, Day 15 Post Booster Dose 1
  35. Percent of Participants Who Seroconverted Against BA.1 for Cohort 2Time frame: Day 43 Post-Dose 1, Day 15 Post Booster Dose 1
  36. Percent of Participants Who Seroconverted Against BA.4/5 for Cohort 2Time frame: Day 43 Post-Dose 1, Day 15 Post Booster Dose 1
  37. Percent of Participants Who Seroconverted Against XBB.1 for Cohort 2Time frame: Day 43 Post-Dose 1, Day 15 Post Booster Dose 1
  38. Percent of Participants Who Seroconverted Against D614G for Cohort 2Time frame: Day 15 Post-Booster Dose 2, Day 29 Post-Booster Dose 2, Day 91 Post-Booster Dose 2, Day 181 Post-Booster Dose 2
  39. Percent of Participants Who Seroconverted Against BA.1 for Cohort 2Time frame: Day 15 Post-Booster Dose 2, Day 29 Post-Booster Dose 2, Day 91 Post-Booster Dose 2, Day 181 Post-Booster Dose 2
  40. Percent of Participants Who Seroconverted Against BA.4/5 for Cohort 2Time frame: Day 15 Post-Booster Dose 2, Day 29 Post-Booster Dose 2, Day 91 Post-Booster Dose 2, Day 181 Post-Booster Dose 2
  41. Percent of Participants Who Seroconverted Against XBB.1 for Cohort 2Time frame: Day 15 Post-Booster Dose 2, Day 29 Post-Booster Dose 2, Day 91 Post-Booster Dose 2, Day 181 Post-Booster Dose 2

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • The Hope Clinic of Emory University

    Decatur, Georgia

  • University of Maryland Baltimore - Institute of Human Virology

    Baltimore, Maryland

  • NYU Langone Vaccine Center

    New York, New York

  • University of Rochester Medical Center - Vaccine Research Unit

    Rochester, New York

  • Cincinnati Children's Hospital Medical Center Vaccine Research Center

    Cincinnati, Ohio

  • University of Pittsburgh - Medicine - Infectious Diseases

    Pittsburgh, Pennsylvania

  • University of Texas Medical Branch

    Galveston, Texas

  • Baylor College of Medicine

    Houston, Texas

  • Kaiser Permanente Washington Health Research Institute

    Seattle, Washington

  • The University of Washington - Virology Research Clinic

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.